Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.

Oncogenic types of human papillomaviruses (HPVs) cause cervical cancer and other malignancies in humans. The HPV E6 oncoprotein is considered to be an attractive therapeutic target since its inhibition can lead to the apoptotic cell death of HPV-positive cancer cells. The HPV type 16 (HPV16) E6-bind...

Full description

Bibliographic Details
Main Authors: Christina Stutz, Eileen Reinz, Anja Honegger, Julia Bulkescher, Johannes Schweizer, Katia Zanier, Gilles Travé, Claudia Lohrey, Karin Hoppe-Seyler, Felix Hoppe-Seyler
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4495056?pdf=render
_version_ 1830412043370364928
author Christina Stutz
Eileen Reinz
Anja Honegger
Julia Bulkescher
Johannes Schweizer
Katia Zanier
Gilles Travé
Claudia Lohrey
Karin Hoppe-Seyler
Felix Hoppe-Seyler
author_facet Christina Stutz
Eileen Reinz
Anja Honegger
Julia Bulkescher
Johannes Schweizer
Katia Zanier
Gilles Travé
Claudia Lohrey
Karin Hoppe-Seyler
Felix Hoppe-Seyler
author_sort Christina Stutz
collection DOAJ
description Oncogenic types of human papillomaviruses (HPVs) cause cervical cancer and other malignancies in humans. The HPV E6 oncoprotein is considered to be an attractive therapeutic target since its inhibition can lead to the apoptotic cell death of HPV-positive cancer cells. The HPV type 16 (HPV16) E6-binding peptide pep11, and variants thereof, induce cell death specifically in HPV16-positive cancer cells. Although they do not encompass the LxxLL binding motif found in cellular HPV16 E6 interaction partners, such as E6AP, the pep11 variants strongly bind to HPV16 E6 by contacting the recently identified E6AP binding pocket. Thus, these peptides can serve as prototype E6-inhibitory molecules which target the E6AP pocket. We here analyzed their intracellular interaction with HPV16 E6. By comprehensive intracellular binding studies and GST pull-down assays, we show that E6-binding competent pep11 variants induce the formation of a trimeric complex, consisting of pep11, HPV16 E6 and p53. These findings indicate that peptides, which do not contain the LxxLL motif, can reshape E6 to enable its interaction with p53. The formation of the trimeric HPV16 E6 / peptide / p53 complex was associated with an increase of endogenous HPV16 E6 protein amounts. Yet, total cellular p53 amounts were also increased, indicating that the E6 / E6AP-mediated degradation of p53 is blocked. These findings suggest that inhibition of oncogenic activities by targeting the E6AP pocket on HPV16 E6 could be a strategy for therapeutic intervention.
first_indexed 2024-12-20T20:00:41Z
format Article
id doaj.art-24b99daa2a4047a9b741b6df754777ac
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-20T20:00:41Z
publishDate 2015-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-24b99daa2a4047a9b741b6df754777ac2022-12-21T19:28:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01107e013233910.1371/journal.pone.0132339Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.Christina StutzEileen ReinzAnja HoneggerJulia BulkescherJohannes SchweizerKatia ZanierGilles TravéClaudia LohreyKarin Hoppe-SeylerFelix Hoppe-SeylerOncogenic types of human papillomaviruses (HPVs) cause cervical cancer and other malignancies in humans. The HPV E6 oncoprotein is considered to be an attractive therapeutic target since its inhibition can lead to the apoptotic cell death of HPV-positive cancer cells. The HPV type 16 (HPV16) E6-binding peptide pep11, and variants thereof, induce cell death specifically in HPV16-positive cancer cells. Although they do not encompass the LxxLL binding motif found in cellular HPV16 E6 interaction partners, such as E6AP, the pep11 variants strongly bind to HPV16 E6 by contacting the recently identified E6AP binding pocket. Thus, these peptides can serve as prototype E6-inhibitory molecules which target the E6AP pocket. We here analyzed their intracellular interaction with HPV16 E6. By comprehensive intracellular binding studies and GST pull-down assays, we show that E6-binding competent pep11 variants induce the formation of a trimeric complex, consisting of pep11, HPV16 E6 and p53. These findings indicate that peptides, which do not contain the LxxLL motif, can reshape E6 to enable its interaction with p53. The formation of the trimeric HPV16 E6 / peptide / p53 complex was associated with an increase of endogenous HPV16 E6 protein amounts. Yet, total cellular p53 amounts were also increased, indicating that the E6 / E6AP-mediated degradation of p53 is blocked. These findings suggest that inhibition of oncogenic activities by targeting the E6AP pocket on HPV16 E6 could be a strategy for therapeutic intervention.http://europepmc.org/articles/PMC4495056?pdf=render
spellingShingle Christina Stutz
Eileen Reinz
Anja Honegger
Julia Bulkescher
Johannes Schweizer
Katia Zanier
Gilles Travé
Claudia Lohrey
Karin Hoppe-Seyler
Felix Hoppe-Seyler
Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
PLoS ONE
title Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
title_full Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
title_fullStr Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
title_full_unstemmed Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
title_short Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
title_sort intracellular analysis of the interaction between the human papillomavirus type 16 e6 oncoprotein and inhibitory peptides
url http://europepmc.org/articles/PMC4495056?pdf=render
work_keys_str_mv AT christinastutz intracellularanalysisoftheinteractionbetweenthehumanpapillomavirustype16e6oncoproteinandinhibitorypeptides
AT eileenreinz intracellularanalysisoftheinteractionbetweenthehumanpapillomavirustype16e6oncoproteinandinhibitorypeptides
AT anjahonegger intracellularanalysisoftheinteractionbetweenthehumanpapillomavirustype16e6oncoproteinandinhibitorypeptides
AT juliabulkescher intracellularanalysisoftheinteractionbetweenthehumanpapillomavirustype16e6oncoproteinandinhibitorypeptides
AT johannesschweizer intracellularanalysisoftheinteractionbetweenthehumanpapillomavirustype16e6oncoproteinandinhibitorypeptides
AT katiazanier intracellularanalysisoftheinteractionbetweenthehumanpapillomavirustype16e6oncoproteinandinhibitorypeptides
AT gillestrave intracellularanalysisoftheinteractionbetweenthehumanpapillomavirustype16e6oncoproteinandinhibitorypeptides
AT claudialohrey intracellularanalysisoftheinteractionbetweenthehumanpapillomavirustype16e6oncoproteinandinhibitorypeptides
AT karinhoppeseyler intracellularanalysisoftheinteractionbetweenthehumanpapillomavirustype16e6oncoproteinandinhibitorypeptides
AT felixhoppeseyler intracellularanalysisoftheinteractionbetweenthehumanpapillomavirustype16e6oncoproteinandinhibitorypeptides